Policy & Regulation
Wilson Therapeutics widens loss in Q1 2018
17 May 2018 -

Biopharmaceutical company Wilson Therapeutics AB (STO:WTX) on Wednesday reported loss of SEK68.9m, or SEK2.43 per diluted share, in Q1 2018, from 1 January 2018 to 31 March 2018.

This was a decline over loss of SEK31.4m, or SEK1.22 per diluted share, in Q1 2017.

Net sales for the quarter were nil, same as in Q1 2017.

During the quarter, the first patient was enrolled in the pivotal phase 3 FOCuS trial.

Wilson Therapeutics develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics' lead product, WTX101, is in phase 3 development as a novel treatment for Wilson Disease.




Related Headlines